Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms.  Treitler PC, Bowden CF, Lloyd J, Enich M, Nyaku AN, Crystal S.  J Subst Abuse Treat. 2022 Jan;132:108514. doi: 10…

Buprenorphine Dispensing in Pennsylvania During the COVID-19 Pandemic, January to October 2020.  Chalasani R, Shinabery JM, Goetz CT, Chang CH, Yang Q, Suda KJ, Gellad WF.  J Gen Intern Med. 2021 Dec;36(12):3915-3917. doi: 10.1007/s11606…

Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C..  Yeo, E.J., Kralles, H., Sternberg, D. et al. Harm Reduct…

Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.  Levander XA, Hoffman KA, McIlveen JW, McCarty D, Terashima JP, Korthuis PT.  Addict Sci Clin Pra…

Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia.  Haggerty T, Khodaverdi M, Dekeseredy P, Wood N, Hendricks B, Peklinsky J, Sedney CL.  J Sub…

Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia.  Lintzeris, N., Deacon, R.M., Hayes, V., Cowan, T., Mills, L., Parvaresh, L., Harvey Dodds, L., Jansen, L., Dojcinovic, R., Leung, M.C…